This site uses technical cookies, Analytics cookies and third-party cookies for the operation of the site and to improve the user experience.
Empowering all doctors to provide the best possible care.
AMBOSS is a medical technology company that has fundamentally changed the way medical knowledge is acquired and utilized at the point of care. Students turn to its interactive library and essential question bank for general study and exam preparation. Clinicians rely on its evidence-based recommendations and guidance to make effective clinical decisions in real time. Today, more than a million health care professionals in over 180 countries rely on AMBOSS.
As a digital platform, AMBOSS provides a current and first-rate medical knowledge resource that is immediately accessible to all those who wish to pursue a medical education and profession, regardless of the socioeconomic challenges they may face. As a company, it aims to pave new professional paths in health care, enabling more and better-trained doctors to enter the field and serve their communities.
BiomeHub is a Biotech/HealthTech startup that works with the development and application of microbiome-based technology, with expertise in molecular biology, genomics, bioinformatics, and data science. The BiomeHub purpose and mission are positively impacting people's lives, developing and applying microbiome-based technologies, assisting in the diagnosis and prognostics of complex diseases and the development of new biomarkers and therapeutic targets. Founded in 2019 in Florianópolis - Brazil, BiomeHub is one of the first and few companies to develop cutting-edge technology for analyzing the human microbiome in South America. With two years in the market, BiomeHub is already a reference human microbiome, nationally recognized.
Botkin.AI is an AI-powered platform for medical images processing and analysis.
The platform is designed to reduce the problem of a shortage of radiologists and to improve the quality of analysis and recognition of diagnostic images using artificial intelligence. It offers a full cycle of workflow, ranging from integration with PACS, depersonification of images and ending with providing radiologists with access to the results of image analysis.The platform also provides work in the mode of "hybrid intelligence" (Human-AI-Loop), with the possibility of additional markup of images by radiologists.
Congo medika is a digital platform bringing together several health professionals (doctors, nurses, laboratory technicians) who offer home health care services through its medical application called "Congo medika" available on google playstore.
HysensBio presents a new paradigm for incurable dental diseases with our Dentopine platform, which reactivates poorly functioning or aged tooth cells. Joo Cheol Park, CEO of HysensBio & a professor at Seoul National University School of Dentistry strengthened first-in-class drug development capabilities through 20 years of research and development.
HysensBio is developing two platform technologies, 1) “Dentopine”, first-in-class therapeutics for dental diseases, and 2) “PACA”, Permanent Adult Cell Activation therapeutics for incurable diseases. HysensBio is now conducting Phase 1/2a Clinical Trial for Dentin Hypersensitivity, which has about 1 billion patients and a market worth US$ 250B in 2027 (Frost & Sullivan, 2021).
MMI S.p.A. was founded in 2015 near Pisa, Italy and offers the Symani Surgical System, a robotic system that enables surgeons to achieve better outcomes on microsurgical procedures. The system combines the world’s smallest wristed microinstruments as well as tremor-reducing and motion-scaling technologies that allow more surgeons to successfully perform microsurgery and expand the field of supermicosurgery.
Nala enables health systems and insurance companies to provide their members with a convenient solution to proactively manage their health via custom-tailored monitoring programs, and live doctors access from the comfort of their homes.
Nalagenetics is a medical technology company focusing on personalized screening and intervention. Nalagenetics aims to provide an affordable and actionable end-to-end genetic testing that is relevant to the local populations. The company has four product pillars: Clinical Decision Support for physicians, genetic tests (currently based on qPCR), Knowledge Base and algorithms to generate clinically actionable reports, and Patient Engagement.
Notch is developing renewable, stem cell-derived immunotherapies, with an initial focus on cancer. We believe that cell therapies can bring value to patients and healthcare systems by being safe, effective, and accessible.
Founded in 2011 by renowned entrepreneurs with the mission to Eliminate Unnecessary Blindness, salauno is an ophthalmology system that works with innovative medical and engineering processes and the latest technology to help reduce the backlog of eye care services.
Sansure Biotech Inc., now a listed company in China, established in 2008, is an integrated solutions manufacturer and provider with independent innovation of molecular diagnostics and gene technology, has over 10-year experience specialized in diagnostic reagents, nucleic acid diagnostic instruments, complete lab solutions and lab chain services. Sansure solutions for molecular diagnosis are compatible with majority of PCR detection instruments and lab environments based on unique technical platforms “global leading magnetic beads extraction system”, “one of the simplest and fastest one-step DNA/RNA lysis systems”, automated nucleic acid extraction system, POCT devices and real-time PCR instruments. Over 40% of its employees work for R&D and technical service departments, over one hundred of products with global registrations, including infectious diseases, cancer, maternal and child health, blood screening, emerging infectious diseases prevention and control, chronic disease management, etc.
During global COVID-19 pandemic, Sansure solutions, precise, fast, simple, easy-to-use and high-throughput, become the major COVID-19 detection solutions in China and other countries, contributing to the world pandemic prevention and control. The full range integrated solution includes " 2019-nCoV nucleic acid diagnostic kit + 2019-nCoV antigen test + 2019-nCoV POCT rapid test + 2019-nCoV/Flu A /Flu B triple test + 2019-nCoV and Six Respiratory Pathogens Nucleic Acid Diagnostic Kit + 2019-nCoV mutant B117 identification test", which can cover the common mutant types reported.
"Sansure solutions" have been widely used in nearly 160 countries worldwide, such as France, UK, Germany, Russia, the Philippines, Brazil etc., obtained certificates in over 65 countries, include NMPA China, US FDA EUA，ANVISA, TGA Australia, We are one of the companies with the largest number of overseas certificates.
TISSIUM is a privately-owned medtech company based in Paris, France and Boston, USA that is dedicated to the development and commercialization of a unique biopolymer platform to address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction.
TISSIUM is developing a portfolio of solutions that leverage its proprietary family of fully biosynthetic, biomorphic and programmable polymers, which are the foundation of the company’s technology platform. Currently, the Company has a pipeline of seven products across three verticals, including nerve repair, hernia and cardiovascular. Each product is designed to enhance the tissue reconstruction process in a unique way. The company also develops delivery and activation devices for enhanced performance and usability of its products.
TISSIUM’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013.